Who owns Eton Pharmaceuticals, Inc. (AVEO)? Elite investor 13F holders

5 tracked elite investors reported holding Eton Pharmaceuticals, Inc as of 2026-09-30, including D.E. Shaw, Cannell Capital, Polen Capital Management, Gotham Asset Management, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawETON PHARMACEUTICALS INCSHARE2026-09-302026-11-16 00:00:003652804.00 USD70942.000000SharesreduceOriginal filing
Cannell CapitalETON PHARMACEUTICALS INCSHARE2026-09-302026-11-16 00:00:003635554.00 USD70607.000000SharesreduceOriginal filing
Polen Capital ManagementETON PHARMACEUTICALS INCSHARE2026-09-302026-11-13 00:00:005357535.00 USD104050.000000SharesaddOriginal filing
Gotham Asset ManagementETON PHARMACEUTICALS INCSHARE2026-09-302026-11-16 00:00:002441656.00 USD47420.000000SharesaddOriginal filing
Renaissance Technologies LLCETON PHARMACEUTICALS INCSHARE2026-09-302026-11-12 00:00:00744494.00 USD14459.000000SharesreduceOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown